- Home
- AVTX vs GAN Comparison
AVTX vs GAN Comparison
Compare AVTX & GAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- GAN
- Stock Information
- Founded
- AVTX 2011
- GAN 1999
- Country
- AVTX United States
- GAN United States
- Employees
- AVTX N/A
- GAN N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- GAN Computer Software: Programming Data Processing
- Sector
- AVTX Health Care
- GAN Technology
- Exchange
- AVTX Nasdaq
- GAN Nasdaq
- Market Cap
- AVTX 90.9M
- GAN 83.2M
- IPO Year
- AVTX 2015
- GAN 2020
- Fundamental
- Price
- AVTX $9.09
- GAN $1.84
- Analyst Decision
- AVTX Strong Buy
- GAN
- Analyst Count
- AVTX 4
- GAN 0
- Target Price
- AVTX $33.00
- GAN N/A
- AVG Volume (30 Days)
- AVTX 141.8K
- GAN 234.6K
- Earning Date
- AVTX 11-07-2024
- GAN 11-08-2024
- Dividend Yield
- AVTX N/A
- GAN N/A
- EPS Growth
- AVTX N/A
- GAN N/A
- EPS
- AVTX N/A
- GAN N/A
- Revenue
- AVTX $820,000.00
- GAN $134,024,000.00
- Revenue This Year
- AVTX N/A
- GAN $5.97
- Revenue Next Year
- AVTX N/A
- GAN $11.32
- P/E Ratio
- AVTX N/A
- GAN N/A
- Revenue Growth
- AVTX N/A
- GAN N/A
- 52 Week Low
- AVTX $3.95
- GAN $1.17
- 52 Week High
- AVTX $34.46
- GAN $1.87
- Technical
- Relative Strength Index (RSI)
- AVTX 37.40
- GAN 54.64
- Support Level
- AVTX $9.00
- GAN $1.81
- Resistance Level
- AVTX $9.99
- GAN $1.86
- Average True Range (ATR)
- AVTX 0.89
- GAN 0.03
- MACD
- AVTX -0.01
- GAN -0.00
- Stochastic Oscillator
- AVTX 27.07
- GAN 49.32
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About GAN GAN Limited
GAN Ltd provides Software-as-a-Service solutions for online casino gaming and sports betting applications. The company has two operating segments B2B and B2C. The B2B segment develops, markets, and sells instances of GameSTACK, GAN Sports, and iSight Back Office technology that incorporates comprehensive player registration, account funding, and back-office accounting and management tools that enable the casino operators to efficiently, confidently, and effectively extend their presence online in places that have permitted online real money gaming, and The B2C segment, which includes the operations of Coolbet, develops and operates a B2C online sports betting and casino platform that is accessible through its website in markets across Northern Europe, Latin America, and Canada.